Predictive value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOPΟ-IIA, TOPOIIB and C-MYC genes in patients with small cell lung cancer (SCLC) who received first line therapy with cisplatin and etoposide.

摘要: Background The aim of the study was to evaluate predictive value genes involved in action cisplatin-etoposide Small Cell Lung Cancer (SCLC). Methods 184 SCLC patients’ primary tumour samples were analyzed for ERCCI, BRCA1, ATP7B, PKM2 TOPOI, TOPOIIA, TOPOIIB and C-MYC mRNA expression. All patients treated with cisplatin-etoposide. Results median age 63 years 120 (65%) had extended stage, 75 (41%) increased LDH serum levels 131 (71%) an ECOG performance status 0-1. Patients limited whose tumours expressed high ERCC1 (p=0.028), (p=0.046), TOPOI (p=0.008), TOPOIIA (p=0.002) (p<0.001) a shorter Progression Free Survival (PFS). In stage patients, expression (p=0.014), (p=0.026), (p=0.021) (p=0.019) correlated decreased overall survival (mOS) while only negative impact on Os (p=0.035). The favorable signature (low ERCC1, PKM2, TOPOIIB) significantly better PFS both LS-SCLC (p<0.001 p=0.007, respectively) ES-SCLC (p=0.007 (p=0.011, group. unfavorable independent predictor poor (HR: 3.18; p=0.002 HR: 3.14; p=0.021) 4.35; p=0.001and 3.32; p=0.019) respectively. Conclusions Single gene’s analysis as well integrated may predict treatment outcome SCLC. These findings should be further validated prospective study.